Olr496 inhibitors represent a specific class of compounds that are designed to target and modulate the activity of the Olr496 protein, which is a member of the olfactory receptor family. Olfactory receptors, typically involved in the detection of odorant molecules, belong to a large family of G-protein-coupled receptors (GPCRs), which are known for their significant role in signal transduction processes across cell membranes. The inhibition of Olr496 involves binding to the receptor in a way that either prevents its activation by natural ligands or interrupts the downstream signaling cascade that would normally result from such activation. This can lead to alterations in the signaling pathways associated with the receptor, which may influence various physiological processes depending on the distribution and specific functions of Olr496 in different tissues or systems.
Structurally, Olr496 inhibitors may vary widely, but they often share key features that allow them to effectively interact with the Olr496 binding site. These features could include specific aromatic or heterocyclic rings that facilitate binding through hydrophobic interactions or hydrogen bonding with the receptor's active site. Additionally, many Olr496 inhibitors are designed to possess sufficient lipophilicity, ensuring their ability to cross cellular membranes and reach the receptor embedded within the lipid bilayer. The design and synthesis of these inhibitors typically involve a combination of computational modeling, structure-activity relationship (SAR) studies, and biochemical assays to optimize their affinity and selectivity for Olr496. Such inhibitors can serve as powerful tools for probing the biological functions of Olr496 in various non-clinical research settings, contributing to a deeper understanding of olfactory receptor mechanisms and GPCR signaling as a whole.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Selectively inhibits ALK tyrosine kinase, potentially affecting proteins in ALK-driven signaling pathways. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially influencing proteins involved in apoptosis and cell survival. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits Bruton's tyrosine kinase, potentially affecting proteins in B-cell receptor signaling. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $82.00 $158.00 | 1 | |
Inhibits Hedgehog signaling pathway, potentially affecting proteins involved in cell growth and differentiation. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGF receptors, potentially affecting proteins involved in angiogenesis and tumor growth. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, potentially affecting proteins involved in the MAPK/ERK pathway. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially affecting proteins in angiogenesis, oncogenesis, and the tumor microenvironment. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Inhibits EGFR with T790M mutation, potentially affecting proteins in mutated EGFR pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially affecting proteins in multiple signaling pathways. | ||||||